RT Journal Article
T1 Bendamustine as part of conditioning of autologous stem cell transplantation in patients with aggressive lymphoma: a phase 2 study from the GELTAMO group.
A1 Redondo, Alba M
A1 Valcárcel, David
A1 González-Rodríguez, Ana P
A1 Suárez-Lledó, María
A1 Bello, José L
A1 Canales, Miguel
A1 Gayoso, Jorge
A1 Colorado, Mercedes
A1 Jarque, Isidro
A1 Del Campo, Raquel
A1 Arranz, Reyes
A1 Terol, María J
A1 Rifón, José J
A1 Rodríguez, María J
A1 Ramírez, María J
A1 Castro, Nerea
A1 Sánchez, Andrés
A1 López-Jiménez, Javier
A1 Montes-Moreno, Santiago
A1 Briones, Javier
A1 López, Aurelio
A1 Palomera, Luis
A1 López-Guillermo, Armando
A1 Caballero, Dolores
A1 Martín, Alejandro
A1 Grupo Español de Linfomas y Trasplante Autólogo de Médula Ósea (GELTAMO), 
K1 BEAM
K1 aggressive lymphomas
K1 autologous stem-cell transplantation
K1 bendamustine
K1 clinical trial
AB We conducted a phase 2 trial to evaluate the safety and efficacy of bendamustine instead of BCNU (carmustine) in the BEAM (BCNU, etoposide, cytarabine and melphalan) regimen (BendaEAM) as conditioning for autologous stem-cell transplantation (ASCT) in patients with aggressive lymphomas. The primary endpoint was 3-year progression-free survival (PFS). Sixty patients (median age 55 [28-71] years) were included. All patients (except one who died early) engrafted after a median of 11 (9-72) and 14 (4-53) days to achieve neutrophil and platelet counts of >0.5 × 109 /l and >20 × 109 /l, respectively. Non-relapse mortality at 100 days and 1 year were 3.3% and 6.7%, respectively. With a median follow-up of 67 (40-77) months, the estimated 3-year PFS and overall survival (OS) were 58% and 75%, respectively. Patients in partial response at study entry had significantly worse PFS and OS than patients who underwent ASCT in complete metabolic remission, and this was the only prognostic factor associated with both PFS (Relative risk [RR], 0.27 [95% confidence interval {CI} [0.12-0.56]) and OS (RR, 0.40 [95% CI 0.17-0.97]) in the multivariate analysis. BendaEAM conditioning is therefore a feasible and effective regimen in patients with aggressive lymphomas. However, patients not in complete metabolic remission at the time of transplant had poorer survival and so should be considered for alternative treatment strategies.
YR 2018
FD 2018-12-12
LK https://hdl.handle.net/10668/25042
UL https://hdl.handle.net/10668/25042
LA en
DS RISalud
RD Apr 7, 2025